Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 1-Year Low – What’s Next?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s share price reached a new 52-week low on Monday . The company traded as low as $28.97 and last traded at $29.18, with a volume of 46245 shares. The stock had previously closed at $29.70.

Analyst Ratings Changes

COLL has been the subject of several analyst reports. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Piper Sandler reissued a “neutral” rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. Finally, HC Wainwright upped their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, September 5th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.60.

Collegium Pharmaceutical Trading Down 1.6 %

The stock has a 50 day moving average of $32.48 and a 200 day moving average of $34.32. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The firm has a market cap of $942.02 million, a P/E ratio of 12.59 and a beta of 0.80.

Institutional Trading of Collegium Pharmaceutical

Hedge funds and other institutional investors have recently bought and sold shares of the company. nVerses Capital LLC boosted its stake in shares of Collegium Pharmaceutical by 1,600.0% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 1,600 shares in the last quarter. GAMMA Investing LLC lifted its stake in Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 792 shares during the last quarter. CWM LLC boosted its position in Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after buying an additional 736 shares during the period. TD Private Client Wealth LLC grew its stake in shares of Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after buying an additional 483 shares during the last quarter. Finally, Virtus Fund Advisers LLC purchased a new position in shares of Collegium Pharmaceutical in the third quarter worth about $72,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.